A Novel Inhibitor of HSP70 Induces Mitochondrial Toxicity and Immune Cell Recruitment in Tumors

Thibaut Barnoud(Medical University of South Carolina), Maureen E. Murphy(The Wistar Institute), Madeline Good(The Wistar Institute), Julia I-Ju Leu(University of Pennsylvania), David W. Speicher(The Wistar Institute), Dmitry I. Gabrilovich(AstraZeneca (Netherlands)), Alexandra Indeglia(Brigham and Women's Hospital), Joel Cassel(The Wistar Institute), Tetyana Martynyuk(The Wistar Institute), Joshua L.D. Parris(The Wistar Institute), Hsin‐Yao Tang(The Wistar Institute), Emilio Sanseviero(The Wistar Institute), Keerthana Gnanapradeepan(C4 Therapeutics (United States)), Adi Narayana Reddy Poli(The Wistar Institute), Rebecca Moeller(Drexel University), Donna L. George(University of Pennsylvania), Jessica C. Leung(The Wistar Institute), Qin Liu(University of Science and Technology of China), Andrew V. Kossenkov(The Wistar Institute), Subhasree Basu(The Wistar Institute), Joseph M. Salvino(The Wistar Institute)
Cancer Research
October 6, 2020
10.1158/0008-5472.can-20-0397
Cited by 29

Related Papers

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
|Journal of Clinical Investigation|2015|1k
Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database
|PROTEOMICS|2005|792
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
|Journal of Biological Chemistry|2002|788
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
|Annual Review of Medicine|2014|505
Classification of current anticancer immunotherapies
|Oncotarget|2014|469